## **Amendments to the Claims**

## 1. (original) A compound of formula I:

$$A \xrightarrow{Y} NR_1R_2$$

wherein

A is selected from -O- and -S-;

X is selected from  $C_2$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_3$ - $C_8$  cycloalkyl and  $C_4$ - $C_8$  cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl- $S(O)_n$ - where n is 0, 1 or 2, -CF<sub>3</sub>, -CN and -CONH<sub>2</sub>;

Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> alkyl-S(O)<sub>n</sub>-where n is 0, 1 or 2, nitro, acetyl, -CF<sub>3</sub>, -SCF<sub>3</sub> and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C<sub>1</sub>-C<sub>4</sub> alkyl;

Z is selected from H, OR<sub>3</sub> or F, wherein R<sub>3</sub> is selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl and phenyl C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sub>1</sub> and R<sub>2</sub> are each independently H or C<sub>1</sub>-C<sub>4</sub> alkyl;

with the proviso that, when Z is H, then Y may not be optionally substituted phenyl or optionally substituted naphthyl.

and pharmaceutically acceptable salts thereof.

- 2. (original) A compound as claimed in claim 1, wherein A is -O-.
- 3. (original) A compound as claimed in claim 1, wherein A is -S-.
- 4. (original) A compound as claimed in any one of the preceding claims, wherein one of  $R_1$  and  $R_2$  is H.
- 5. (currently amended) A compound as claimed in any one of the preceding elaims claim 2, wherein one of  $R_1$  and  $R_2$  is H and the other is methyl.
- 6. (currently amended) A compound as claimed in any one of the preceding elaims claim 1, wherein the compound possesses the stereochemistry defined in formula II

7. (currently amended) A compound as claimed in any one of claims 1 – 5 claim 1, wherein the compound possesses the stereochemistry defined in formula III

$$X \xrightarrow{A}^{Y} NR_1R_2$$

III

- 8. (currently amended) A compound as claimed in any one of the preceding elaims claim 5 wherein Z is H.
- 9. (currently amended) A compound as claimed in any one of the preceding elaims claim 5, wherein X is  $C_2$ - $C_8$  alkyl which may be optionally substituted with up to 3 substituents each independently selected from halo,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl- $S(O)_n$  where n is 0, 1 or 2, -CF<sub>3</sub>, -CN and -CONH<sub>2</sub>.
- 10. (original) A compound as claimed in claim 9 wherein X is selected from ethyl, n-propyl, i-propyl, n-butyl, i-butyl, n-pentyl, i-pentyl, neopentyl, 3,3-dimethylbutyl and 2-ethylbutyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and -CF<sub>3</sub>.
- 11. (original) A compound as claimed in claim 10 wherein X is selected from n-propyl, i-propyl, n-butyl and i-butyl.
- 12. (currently amended) A compound as claimed in any one of claims 1 to claim 8, wherein X is  $C_2$ - $C_8$  alkenyl which may be optionally substituted with up to 3 substituents each independently selected from halo,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl- $S(O)_n$  where n is 0, 1 or 2, -CF<sub>3</sub>, -CN and -CONH<sub>2</sub>.
- 13. (original) A compound as claimed in claim 12 wherein X is 2-methyl-2-propenyl.
- 14. (currently amended) A compound as claimed in any one of claims 1 to claim 8, wherein X is  $C_4$ - $C_8$  cycloalkylalkyl which may be optionally substituted with up to 3 substituents each independently selected from halo,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl- $S(O)_n$  where n is 0, 1 or 2, -CF3, -CN and -CONH<sub>2</sub>.

- 15. (original) A compound as claimed in claim 14 wherein X is selected from cyclohexylmethyl and cyclopropylmethyl.
- 16. (currently amended) A compound as claimed in any one of the preceding elaims claim 5, wherein Y is phenyl optionally substituted with up to 5 substituents each independently selected from halo, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> alkyl-S-, CF<sub>3</sub>, and -SCF<sub>3</sub>.
- 17. (original) A compound as claimed in claim 16, wherein Y is phenyl optionally substituted with up to 2 substituents each independently selected from F, Cl, Br, I, Me, Et, OMe, SMe, -CF<sub>3</sub>, and -SCF<sub>3</sub>.
- 18. (currently amended) A compound as claimed in any one of claims 1–15 claim 5, wherein Y is naphthyl optionally substituted with up to 5 substituents each independently selected from halo, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> alkyl-S(O)<sub>n</sub>-where n is 0, 1 or 2, nitro, acetyl, -CF<sub>3</sub>, -SCF<sub>3</sub> and cyano.
- 19. (original) A compound as claimed in claim 18, wherein Y is unsubstituted naphthyl or naphthyl which is mono-substituted with a substituent selected from halo, C<sub>1</sub>-C<sub>4</sub> alkyl and -CF<sub>3</sub>.
- 20. (original) A compound as claimed in claim 19 wherein the substituent is located at the 4-position of the naphthyl ring.
- 21. (currently amended) A compound as claimed in any one of claims 18 20 claim 20, wherein the point of attachment of the optionally substituted naphthyl group to the -O- or -S- atom is attachment at the 1 position.
- 22. (currently amended) A compound as claimed in any one of the claims 1-15 claim 8, wherein Y is benzofuranyl, benzothiazolyl, benzoisothiazolyl or indolyl each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> alkyl-

 $S(O)_n$ - where n is 0, 1 or 2, nitro, acetyl, -CF<sub>3</sub>, -SCF<sub>3</sub> and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from  $C_1$ - $C_4$  alkyl.

- 23. (original) A compound as claimed in claim 22, wherein Y is benzofuranyl, benzoisothiazolyl or indolyl each of which may be optionally mono-substituted with Me; and when Y is indolyl it may be substituted or further substituted by an N-methyl substituent.
- 24. (currently amended) A compound as claimed in any one of claims 22- claim 23, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 7 position.
- 25. (currently amended) A compound as claimed in any one of claims 22- claim 23, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 4 position.
- 26. (currently amended) A compound as claimed in any one of the claims 1-15 claim 8, wherein Y is benzothienyl optionally substituted with up to 5 substituents each independently selected from halo,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl- $S(O)_n$  where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano.
- 27. (original) A compound as claimed in claim 26, wherein Y is benzothienyl optionally substituted with up to 2 substituents each independently selected from halo, C<sub>1</sub>-C<sub>4</sub> alkyl, -CF<sub>3</sub> and cyano.
- 28. (currently amended) A compound as claimed in any one of claims 26- claim 27, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 7 position.

- 29. (currently amended) A compound as claimed in any one of claims 26- claim 27, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 4 position.
- 30. (currently amended) A compound as claimed in any one of claims 26-claim 27, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 5 position.
- 31. (currently amended) A compound as claimed in any one of claims 26- claim 27, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 6 position.
- 32. (currently amended) A compound as claimed in any one of the claims 1-15 claim 8, wherein Y is quinolyl or isoquinolyl each of which may be optionally substituted with up to 5 substituents each independently selected from halo,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl- $S(O)_n$  where n is 0, 1 or 2, nitro, acetyl, - $CF_3$ , - $SCF_3$  and cyano.
- 33. (original) A compound as claimed in claim 32, wherein Y is quinolyl or isoquinolyl each of which may be optionally mono-substituted with a halogen atom.
- 34. (currently amended) A compound as claimed in claim 32 or 33, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 8 position.
- 35. (currently amended) A compound as claimed in claim 32 or 33, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 5 position.
- 36. (currently amended) A compound as claimed in any one of the claims 1-15 claim 8, wherein Y is thienopyridyl which may be optionally substituted with up to 4

substituents each independently selected from halo,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl- $S(O)_n$ - where n is 0, 1 or 2, nitro, acetyl, -CF<sub>3</sub>, -SCF<sub>3</sub> and cyano.

- 37. (original) A compound as claimed in claim 36, wherein Y is unsubstituted thieno-[2,3-b]pyridyl or unsubstituted thieno-[2,3-c]pyridyl.
- 38. (currently amended) A compound as claimed in claim <del>36 or</del> 37, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 7 position.
- 39. (currently amended) A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1-38 claim 1, together with a pharmaceutically acceptable diluent or carrier.
- 40. 49. (cancelled)
- 50. (currently amended) A method for treating disorders associated with serotonin and norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1-38 claim 1.
- 51. (original) A method as claimed in claim 50, wherein the disorder is selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation, hot flashes/flushes and pain.
- 52. (original) A method as claimed in claim 51, wherein the disorder is pain.